| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Medical Food Improves Nutritional, Cognitive Status of Patients With Mild Alzheimer's Disease: Presented at ADI By Jenny Powers THESSALONIKI, Greece -- March 13, 2010 -- Data from a study presented here at the 25th Conference of Alzheimer’s Disease International (ADI) on March 11 demonstrated that a medical food containing a combination of nutrients significantly lowered homocysteine levels and improved cognitive function, especially delayed memory, in patients with mild Alzheimer’s disease (AD). Frank H. Pistoor, PhD, Nutricia Advanced Medical Nutrition, Schiphol, the Netherlands, delivered the results of the randomised, double-blind, controlled trial. The medical food was developed following 10 years of research on the impact of nutrients on cognitive function in patients with AD. It contains nutrients such as omega 3 fatty acid, choline, and antioxidants that are substrates for the synthesis of nerve synapses. The study involved 212 drug-naïve patients with mild AD. Half of the patients received the medical food and the other received placebo over the course of 12 weeks. Cognitive function was evaluated using a delayed verbal memory task (Wechsler Memory Scale-revised) and the 13-item modified Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog). Significant benefit in cognitive function from baseline was observed in patients receiving the medical food, as demonstrated by an improvement on the delayed verbal memory task, compared with patients receiving placebo (P = .026). No improvement in scores was seen in the control group. A significant improvement was also seen in the Mini-Mental State Examination score of 40% of the treated patients (P = .011). The treated patients also had a significant decrease in homocysteine levels, compared with patients in the placebo group (P = .001) Although unadjusted analyses showed no significant effect on ADAS-cog, baseline ADAS-cog score was a predictor for the intervention effect (ie, patients with a higher baseline score showed a greater effect of the medical food). Two 24-week studies, which began in 2009, are expected to confirm these results. Results of both clinical studies are to be expected soon. Funding for this study was provided by Nutricia Advanced Medical Nutrition. [Presentation title: Efficacy of a Medical Food (Souvenaid) in Mild Alzheimer’s Disease: A Randomized Controlled Trial]
|